On October 13, 2026 enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, reported that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Two community key opinion leaders (KOLs) from Colorado Urology, David J. Cahn, MD and Suzanne B. Merrill, MD, FACS, will review clinical case studies and discuss various real-world treatment considerations. To register, click here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Surfactants have been shown to boost efficacy with other NMIBC gene therapies in preclinical models and were subsequently incorporated into clinical development of those gene therapies. enGene is currently enrolling high-risk, BCG-unresponsive NMIBC patients with CIS in an additional cohort in its ongoing LEGEND trial, which incorporates a short surfactant bladder rinse (generic name: polidocanol) prior to intravesical administration of detalimogene. Detalimogene is an investigational, non-viral gene therapy for the treatment of high-risk, NMIBC.

A live question and answer session will follow the formal presentations.

About David J. Cahn, MD

Dr. Cahn is a board-certified urologist with fellowship training in neurourology. He brings years of extensive experience to complex urological conditions that require surgical intervention. Involved with InterStim technology since its approval by the Food and Drug Administration (FDA) in 1998, Dr. Cahn is one of Colorado’s most experienced minimally invasive surgeons treating overactive bladder. Dr. Cahn also specializes in advanced prostate cancer while still maintaining an active general urology practice. In addition, he serves as the Medical Director for Colorado Clinical Research, leading the practice’s clinical trials program.

Dr. Cahn has been in private practice since 1998 and founded Foothills Urology in 2000, now Colorado Urology. He is a member of the Colorado Urology Executive Council.

Dr. Cahn received his medical degree from Albert Einstein College of Medicine in the Bronx, New York, and his bachelor’s degree at Wesleyan University. He completed his residency in urology at Montefiore Medical Center in the Bronx, New York, and his fellowship training in neurourology and female urology at the University of Colorado School of Medicine. He is board-certified by the American Board of Urology.

About Suzanne B. Merrill, MD, FACS

Dr. Suzanne B. Merrill is a board-certified urologist who is fellowship trained in Urologic Oncology. She specializes in the treatment of all cancers of the urinary tract, including bladder, upper tract/urothelial, kidney, prostate, testicular, adrenal, and penile cancer. Dr. Merrill utilizes robotic, minimally invasive as well as open surgical techniques to offer her patients with individualized and top-of-class treatment options. After a career in academic medicine, she transitioned to Colorado Urology where she became the bladder cancer and advanced therapeutic regional leader for the organization. In these roles, she ensures patients at Colorado Urology have access to the most cutting-edge bladder and kidney cancer FDA approved treatments as well as opportunities to engage in clinical trials that deliver highly anticipated novel therapies.

Dr. Merrill completed her bachelor’s degree with summa cum laude honors at The University of Delaware and obtained her Medical Doctorate at The University of North Carolina – Chapel Hill School of Medicine. She completed her residency at Duke University, followed by a Society of Urologic Oncology fellowship at The Mayo Clinic in Rochester, Minnesota. While at the Mayo Clinic, she also received a certificate in Translational Research. Prior to joining Colorado Urology, she was an Associate Professor of Urologic Oncology and Residency Program Director at Penn State Hershey Medical Center in Pennsylvania, where she was recognized with awards for her outstanding faculty leadership and mentorship, as well as humanism and professionalism in surgery.

(Press release, enGene Therapeutics, OCT 13, 2026, View Source [SID1234673367])